Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19871016 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL3614148 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL3507282 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL3507280 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL5422419 | 0.77 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL22321971 | 0.77 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL5422423 | 0.77 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL3504997 | 0.77 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL3505000 | 0.77 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| SCHEMBL14963179 | 0.76 | TP53 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829568-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-7829568-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| EP-1869038-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-07-08 | — | — | EP | disclosed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | CYP3A7, CYP3A5, CYP2D6 | SMN1; SMN2 1159/4885CA14 4471/4885CA12 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.